Masaru Mimura, MD, PhD

  • 14Articles
  • 81.7KReads
  • 2012–2022Active
  • 61Collaborators
  • 206Citations

About

Masaru Mimura, MD, PhD is affiliated with Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. Masaru Mimura has authored or co-authored 14 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2012 and 2022. Their work focuses on Schizophrenia/Schizoaffective Disorders, Depression (MDD), Alzheimer Disease, Neurology, and Bipolar Disorder.

Publications

JCP
Machine Learning Prediction of ECT Responses
Original Research

Machine Learning Prediction of ECT Responses

August 24, 2022

Predicting individual therapeutic outcomes would be clinically useful to help patients accept electroconvulsive therapy (ECT) for treating depression. This study sought to develop a prediction model for ECT response...
, , , et al
JCP
Original Research

Psychiatric Disorders in Patients with PE and AMI

November 9, 2021

This study compared proportions of patients with comorbid psychiatric disorders among those hospitalized for either pulmonary embolism, a common cause of sudden cardiac arrest in psychiatric patients, or acute...
, , , et al
JCP
Meta-Analysis

Single vs Multiple Dose Regimens of Psychotropic Drugs

February 23, 2021

Single-daily-dose regimens are easier for patients to follow than multiple-dose regimens and may increase adherence. But do they work as well? And are they safe? Read this meta-analysis to...
, , , et al
JCP
Review Article

Central and Peripheral Pharmacokinetics of Antipsychotics

July 28, 2020

Pharmacokinetics of antipsychotics are generally slower centrally than peripherally. This review examined the possible dissociation between central D2 receptor occupancy with antipsychotics and their peripheral blood concentrations.
, , , et al
JCP
Original Research

Early Improvements Predict Treatment Response in Alzheimer's

February 11, 2020

Can overall response to antipsychotics be predicted by early improvements in individual symptoms among Alzheimer's disease patients? The current report analyzes the CATIE-AD phase 1 dataset in an attempt...
, , , et al
JCP
Original Research

Placebo Effects in LAI Trials for Schizophrenia

December 4, 2018

Poor treatment adherence masks the true extent of placebo effects in trials of antipsychotics in schizophrenia. Can use of an injectable placebo in double-blind trials of long-acting injectable antipsychotics...
, , , et al
JCP
Original Research

Placebo Effects in the Treatment of Alzheimer's Disease

October 17, 2017

Placebo effects are a common obstacle in the search for Alzheimer's disease treatments. This analysis of data from the large CATIE-AD study investigates ways to screen out potential placebo...
, , , et al
JCP
Original Research

CBT for Pharmacotherapy-Resistant Depression

February 28, 2017

Read a randomized control trial examining whether adding cognitive-behavioral therapy (CBT) for Pharmacotherapy-Resistant Depression improves outcomes.
, , , et al
JCP
Article

Predicting Recovery in Bipolar Depression

February 22, 2017

A key to improving prognosis in bipolar depression may lie in analysis of specific symptoms. This reanalysis of the STEP-BD dataset provides clues to help you determine which patients...
, , , et al
JCP
Article

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial

October 26, 2016

When your patients with schizophrenia insufficiently respond to antipsychotic treatment, do you increase the dose? Do you check their plasma drug concentration? Read this CME article to find out...
, , , et al
JCP
Article

Whether to Increase or Maintain Dosage of Mirtazapine in Early Nonimprovers With Depression

April 22, 2015

, , , et al
JCP
Original Research

Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D2 Receptor Occupancy in Stable Patients With Schizophrenia: Findings From an Open-Label, Randomized, Controlled Study

July 22, 2014

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe